Drug Discovery World

JANUARY 26, 2023

This is the latest episode of the free narrated DDW podcast, “CRO’s and targeted protein degradation offer an exciting future”. They are called “ CROs: Drug discovery expertise on hand ” and “ Why the emergence of targeted protein degradation is so exciting ”.

Targeted Protein Degradation 130

Targeted Protein Degradation Drugs Marketing Research 130

Drug Discovery World

JULY 19, 2024

Biotechnology company Draupnir Bio has received equity investments totalling €12 million to support the company’s work in the field of targeted protein degradation (TPD).

Targeted Protein Degradation 130

Targeted Protein Degradation Small Molecule Research Government 130

Drug Discovery World

OCTOBER 16, 2023

Professor Henrik Daub , Founder and CSO, NEOsphere Biotechnologies looks at the advancements taking place in proteomics and how targeted protein degradation represents a promising approach for developing new treatments for life-threatening diseases. PROTAC targeted protein degraders: the past is prologue.

Targeted Protein Degradation 148

Targeted Protein Degradation Small Molecule Molecular Biology Treatment 148

BMG Labtech

APRIL 16, 2024

Promising future Molecular glues offer exciting opportunities for targeted protein degradation and new ways to reach some of the estimated 85% of undruggable targets in the proteome. Conventional drug development has often focused on finding small molecules that fit the active site of a protein.

Targeted Protein Degradation 40

Targeted Protein Degradation Small Molecule Drug Development Disease 40

Drug Discovery World

DECEMBER 27, 2023

Dr Pierre Eftehkari, Chief Scientific Officer of Inoviem Scientific, joined the podcast series to share his insight into the future of drug development, leaning on his in-depth understanding of the pharmaceutical industry and its needs. and seizure liability testing What are the benefits of a target safety assessment?

Targeted Protein Degradation 174

Targeted Protein Degradation Clinical Trials Pharma Companies Drug Development 174

Drug Discovery World

MARCH 22, 2023

Oxford Drug Design and PhoreMost advance novel cancer therapeutics Oxford Drug Design has been engaged by PhoreMost to accelerate a targeted protein degradation discovery programme for novel cancer therapeutics.

Targeted Protein Degradation 130

Targeted Protein Degradation Small Molecule Drugs Licensing 130

Drug Discovery World

OCTOBER 6, 2022

With key players including AstraZeneca, Bayer, Novartis and Pfizer pushing the boundaries of drug development, the reason behind this growth is evident. This growth is due to factors including a rise in speciality medicines, an increase in lifestyle-driven diseases and a growing population 1. Volume 23 – Issue 4, Fall 2022.

Targeted Protein Degradation 130

Targeted Protein Degradation Drugs Pharma Companies Marketing 130